Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 8/20 | 0.50 |
| ▸ | EGFR | P00533 | 3/20 | 0.46 |
| ▸ | ITK | Q08881 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.41 |
| ▸ | INSR | P06213 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | STK17B | O94768 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5414041 | 0.87 | STK17A (0.44) | EGFRITKHDAC3HDAC1HDAC2 | |
| SCHEMBL5410091 | 0.84 | APEX1 (0.53) | HDAC3HDAC1HDAC2HDAC6STK17A | |
| SCHEMBL5418427 | 0.83 | HDAC3 (0.47) | EGFRITKHDAC3HDAC1HDAC2 | |
| SCHEMBL5422198 | 0.83 | STK17A (0.42) | EGFRHDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL5418520 | 0.83 | LRRK2 (0.49) | BTKEGFRITKHDAC3HDAC1 | |
| SCHEMBL5414042 | 0.81 | STK17A (0.43) | EGFRHDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL5415948 | 0.81 | HDAC3 (0.49) | EGFRHDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL5413822 | 0.80 | CYP3A4 (0.53) | EGFRHDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL5408198 | 0.80 | HDAC3 (0.48) | HDAC3HDAC1HDAC2HDAC6STK17A | |
| SCHEMBL5415421 | 0.80 | STK17A (0.48) | HDAC3HDAC1HDAC2HDAC6STK17A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166599-B2 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-01-23 | — | — | US | disclosed |
| US-20050090486-A1 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-04-28 | — | — | US | disclosed |
| US-20030134838-A1 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134838-A1 | Trisubstituted pyrimidines | APP, PSEN1, BACE1 | BTK 1813/4885EGFR 3316/4885ITK 1783/4885 |
| US-20050090486-A1 | Trisubstituted pyrimidines | APP, BACE1, PSEN1 | BTK 695/4885EGFR 3952/4885ITK 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.